+

WO2008035359A3 - Oximinophenoxyalkanoic acid and phenylalkanoic acid derivatives - Google Patents

Oximinophenoxyalkanoic acid and phenylalkanoic acid derivatives Download PDF

Info

Publication number
WO2008035359A3
WO2008035359A3 PCT/IN2007/000226 IN2007000226W WO2008035359A3 WO 2008035359 A3 WO2008035359 A3 WO 2008035359A3 IN 2007000226 W IN2007000226 W IN 2007000226W WO 2008035359 A3 WO2008035359 A3 WO 2008035359A3
Authority
WO
WIPO (PCT)
Prior art keywords
acid
oximinophenoxyalkanoic
phenylalkanoic
derivatives
preparation
Prior art date
Application number
PCT/IN2007/000226
Other languages
French (fr)
Other versions
WO2008035359A2 (en
Inventor
Braj Bhushan Lohray
Vidya Bhushan Lohray
Harikishore Pingali
Pankaj Ramanbhai Patel
Original Assignee
Cadila Healthcare Ltd
Braj Bhushan Lohray
Vidya Bhushan Lohray
Harikishore Pingali
Pankaj Ramanbhai Patel
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cadila Healthcare Ltd, Braj Bhushan Lohray, Vidya Bhushan Lohray, Harikishore Pingali, Pankaj Ramanbhai Patel filed Critical Cadila Healthcare Ltd
Publication of WO2008035359A2 publication Critical patent/WO2008035359A2/en
Publication of WO2008035359A3 publication Critical patent/WO2008035359A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/88—Oxygen atoms
    • C07D239/90—Oxygen atoms with acyclic radicals attached in position 2 or 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C251/00—Compounds containing nitrogen atoms doubly-bound to a carbon skeleton
    • C07C251/32—Oximes
    • C07C251/34—Oximes with oxygen atoms of oxyimino groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
    • C07C251/48—Oximes with oxygen atoms of oxyimino groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals with the carbon atom of at least one of the oxyimino groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C251/00—Compounds containing nitrogen atoms doubly-bound to a carbon skeleton
    • C07C251/32—Oximes
    • C07C251/50—Oximes having oxygen atoms of oxyimino groups bound to carbon atoms of substituted hydrocarbon radicals
    • C07C251/52—Oximes having oxygen atoms of oxyimino groups bound to carbon atoms of substituted hydrocarbon radicals of hydrocarbon radicals substituted by halogen atoms or by nitro or nitroso groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/32—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D207/33—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D207/333—Radicals substituted by oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/80—[b, c]- or [b, d]-condensed
    • C07D209/82—Carbazoles; Hydrogenated carbazoles
    • C07D209/86—Carbazoles; Hydrogenated carbazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the ring system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/08—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D263/16—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D263/18—Oxygen atoms
    • C07D263/20—Oxygen atoms attached in position 2
    • C07D263/24—Oxygen atoms attached in position 2 with hydrocarbon radicals, substituted by oxygen atoms, attached to other ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/34—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings
    • C07D265/36—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings condensed with one six-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/34—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings
    • C07D265/38—[b, e]-condensed with two six-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/24—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/22—Radicals substituted by doubly bound hetero atoms, or by two hetero atoms other than halogen singly bound to the same carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention discloses oximinophenoxyalkanoic acid and phenylalkanoic acid of the general formula (I) their tautomeric forms, their stereoisomers, their pharmaceutically acceptable salts, pharmaceutical compositions containing them, methods for their preparation, use of these compounds in medicine and the intermediates involved in their preparation.
PCT/IN2007/000226 2006-06-12 2007-06-05 Oximinophenoxyalkanoic acid and phenylalkanoic acid derivatives WO2008035359A2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
IN913MU2006 2006-06-12
IN913/MUM/2006 2006-06-12
IN2167/MUM/2006 2006-12-29
IN2167MU2006 2006-12-29

Publications (2)

Publication Number Publication Date
WO2008035359A2 WO2008035359A2 (en) 2008-03-27
WO2008035359A3 true WO2008035359A3 (en) 2008-05-15

Family

ID=39032144

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IN2007/000226 WO2008035359A2 (en) 2006-06-12 2007-06-05 Oximinophenoxyalkanoic acid and phenylalkanoic acid derivatives

Country Status (1)

Country Link
WO (1) WO2008035359A2 (en)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2025674A1 (en) 2007-08-15 2009-02-18 sanofi-aventis Substituted tetra hydro naphthalines, method for their manufacture and their use as drugs
CN102197019A (en) * 2008-10-27 2011-09-21 卡迪拉保健有限公司 Thyroid receptor ligands
ES2403120T3 (en) * 2008-12-24 2013-05-14 Cadila Healthcare Limited New oxime derivatives
JP2012116753A (en) * 2009-03-26 2012-06-21 Nippon Chemiphar Co Ltd Activating agent for peroxisome proliferator-activated receptor
WO2011107494A1 (en) 2010-03-03 2011-09-09 Sanofi Novel aromatic glycoside derivatives, medicaments containing said compounds, and the use thereof
US8933024B2 (en) 2010-06-18 2015-01-13 Sanofi Azolopyridin-3-one derivatives as inhibitors of lipases and phospholipases
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
PT2658851E (en) * 2010-12-28 2015-06-03 Cadila Healthcare Ltd Heterocyclic compounds suitable for the treatment of dyslipidemia
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2567959B1 (en) 2011-09-12 2014-04-16 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013045413A1 (en) 2011-09-27 2013-04-04 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2014192023A1 (en) * 2013-05-22 2014-12-04 Cadila Healthcare Limited Novel compounds suitable for the treatment of dyslipidemia
EP3083587B1 (en) * 2013-12-16 2018-04-04 Cadila Healthcare Limited Oximino derivatives for the treatment of dyslipidemia
KR20200072795A (en) * 2018-12-13 2020-06-23 고려대학교 산학협력단 Pharmaceutical composition for preventing or treating circadian clock related disease comprising oxyiminomethylbenzene derivatives
KR102209201B1 (en) * 2020-06-29 2021-02-01 고려대학교 산학협력단 Oxyiminomethylbenzene derivatives

Citations (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2003430A1 (en) * 1969-01-31 1970-09-03 Fournier Gmbh Lab Phenoxyacetic acid derivs
GB1352723A (en) * 1970-09-10 1974-05-08 Merck & Co Inc 2-phenyl-benzoxazoles and their production and use
DE2065956A1 (en) * 1969-01-31 1977-07-14 Fournier Gmbh Lab Phenoxyacetic acid derivs
EP0002666A1 (en) * 1977-11-21 1979-07-11 Hoechst Aktiengesellschaft 1,2-Benzisoxazolyloxy (or thio) acetic acids and related compounds, process for their preparation and medicines containing them
US4259509A (en) * 1977-02-14 1981-03-31 Albert Rolland S.A. 2-Methyl-2-phenoxy-propionic acid derivatives, process for their preparation and therapeutical applications thereof
US4999345A (en) * 1988-06-04 1991-03-12 Basf Aktiengesellschaft Sulfonamide derivatives and drugs obtained therefrom
EP0656348A2 (en) * 1993-12-03 1995-06-07 F. Hoffmann-La Roche Ag Aceric acid derivatives as medicaments
WO1995019976A1 (en) * 1994-01-25 1995-07-27 Biocode S.A. Heterocyclic chemoluminescent derivatives
US6355796B1 (en) * 1999-02-16 2002-03-12 Basf Aktiengesellschaft Processes and intermediate compounds for the preparation of 2-(N,N-disubstituted) amino-4-(perfluoroalkyl)-1, 3- oxazin-6-one and 6-(perfluoroalkyl) uracil compounds
WO2002096894A1 (en) * 2001-05-31 2002-12-05 Glaxo Group Limited Thiazole or oxazole derivatives which are useful in the treatment of cardiovascular and related diseases
US6518290B1 (en) * 1999-12-02 2003-02-11 Michael Lawrence Sierra Substituted oxazoles and thiazoles derivatives as HPPAr alpha activators
EP1310494A1 (en) * 2000-08-11 2003-05-14 Nippon Chemiphar Co., Ltd. PPAR (delta) ACTIVATORS
WO2005035495A2 (en) * 2003-10-08 2005-04-21 Nicholas Piramal India Limited Fibrinogen receptor antagonists and their use
WO2005113519A1 (en) * 2004-05-14 2005-12-01 Irm Llc Compounds and compositions as ppar modulators
WO2006011669A1 (en) * 2004-07-28 2006-02-02 Santen Pharmaceutical Co., Ltd. Novel cinnamic acid related compounds
WO2007028424A1 (en) * 2005-02-15 2007-03-15 F. Hoffmann-La Roche Ag Amide derivatives as ppar activators

Patent Citations (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2003430A1 (en) * 1969-01-31 1970-09-03 Fournier Gmbh Lab Phenoxyacetic acid derivs
DE2250327A1 (en) * 1969-01-31 1973-04-26 Fournier Gmbh Lab NEW PHENOXYCARBONIC ACID DERIVATIVES, THEIR PRODUCTION AND THE PHARMACEUTICAL PRODUCTS CONTAINED
DE2065956A1 (en) * 1969-01-31 1977-07-14 Fournier Gmbh Lab Phenoxyacetic acid derivs
GB1352723A (en) * 1970-09-10 1974-05-08 Merck & Co Inc 2-phenyl-benzoxazoles and their production and use
US4259509A (en) * 1977-02-14 1981-03-31 Albert Rolland S.A. 2-Methyl-2-phenoxy-propionic acid derivatives, process for their preparation and therapeutical applications thereof
EP0002666A1 (en) * 1977-11-21 1979-07-11 Hoechst Aktiengesellschaft 1,2-Benzisoxazolyloxy (or thio) acetic acids and related compounds, process for their preparation and medicines containing them
US4999345A (en) * 1988-06-04 1991-03-12 Basf Aktiengesellschaft Sulfonamide derivatives and drugs obtained therefrom
EP0656348A2 (en) * 1993-12-03 1995-06-07 F. Hoffmann-La Roche Ag Aceric acid derivatives as medicaments
WO1995019976A1 (en) * 1994-01-25 1995-07-27 Biocode S.A. Heterocyclic chemoluminescent derivatives
US6355796B1 (en) * 1999-02-16 2002-03-12 Basf Aktiengesellschaft Processes and intermediate compounds for the preparation of 2-(N,N-disubstituted) amino-4-(perfluoroalkyl)-1, 3- oxazin-6-one and 6-(perfluoroalkyl) uracil compounds
US6518290B1 (en) * 1999-12-02 2003-02-11 Michael Lawrence Sierra Substituted oxazoles and thiazoles derivatives as HPPAr alpha activators
EP1310494A1 (en) * 2000-08-11 2003-05-14 Nippon Chemiphar Co., Ltd. PPAR (delta) ACTIVATORS
WO2002096894A1 (en) * 2001-05-31 2002-12-05 Glaxo Group Limited Thiazole or oxazole derivatives which are useful in the treatment of cardiovascular and related diseases
WO2005035495A2 (en) * 2003-10-08 2005-04-21 Nicholas Piramal India Limited Fibrinogen receptor antagonists and their use
WO2005113519A1 (en) * 2004-05-14 2005-12-01 Irm Llc Compounds and compositions as ppar modulators
WO2006011669A1 (en) * 2004-07-28 2006-02-02 Santen Pharmaceutical Co., Ltd. Novel cinnamic acid related compounds
WO2007028424A1 (en) * 2005-02-15 2007-03-15 F. Hoffmann-La Roche Ag Amide derivatives as ppar activators

Non-Patent Citations (10)

* Cited by examiner, † Cited by third party
Title
AKERBLOM, E.B. ET AL.: "Six new photolabile linkers for solid-phase synthesis. 1. Methods of preparation", MOLECULAR DIVERSITY, vol. 3, 1998, pages 137 - 148, XP002472861 *
BORSCHE, W. ET AL.: "Über Kern-acylierungen nach Friedel-Crafts. III", JUSTUS LIEBIGS ANNALEN DER CHEMIE, vol. 553, 1942, pages 260 - 277, XP009097086 *
DE LUCA, L. ET AL.: "A new supported reagent for the photochemical generation of radicals in solution", ORG. LETT., vol. 3, no. 6, 2001, pages 855 - 857, XP002472862 *
DUBOIS, G.E. ET AL.: "Dihydrochalcone Sweeteners. A study of the Atypical Temporal Phenomena", J. MED. CHEM., vol. 24, no. 4, 1981, pages 408 - 428, XP002345673, ISSN: 0022-2623 *
LI, G. ET AL.: "Synthesis of novel phenoxy-linked diazirine glycero- and sphingolipid probes via trialkylaryltin intermediates", TETRAHEDRON LETTERS, vol. 41, no. 35, 2000, pages 6737 - 6741, XP004213940 *
MASSOLINI, G. ET AL.: "SULL'ATTIVITÀ ANTIFUNGINA FITOIATRICA DI ALCUNE BENZOFENONOSSIME", IL FARMACO, ED. SC., vol. 42, no. 2, 1987, pages 117 - 124, XP002047980, ISSN: 0014-827X *
PLATTNER, J. J. ET AL.: "[(AMINOMETHYL)ARYLOXY]ACETIC ACID ESTERS. A NEW CLASS OF HIGH- CEILING DIURETICS. 3. VARIATION IN THE BRIDGE BETWEEN THE AROMATIC RINGS TO COMPLETE MAPPING OF THE RECEPTOR", J. MED. CHEM., vol. 28, no. 1, 1985, pages 79 - 93, XP002022320, ISSN: 0022-2623 *
SAWADA, S. ET AL.: "Improved synthesis of 4-[(R,S)-1-[1-(9H-fluoren-9yl)-methoxycarbonylamino]-(2',4'-dimethoxybenzyl]phenoxyacetic acid as a peptide-resin linker in the solid-phase synthesis of peptide-amides", BIOSCI. BIOTECH. BIOCHEM., vol. 56, no. 9, 1992, pages 1506 - 1507, XP002472860 *
TORRES Y GONZALES, C.: "No. 143. Sur quelques benzhydrylamines para-alcoxylées", BULL. SOC. CHIM. FR, vol. 37, no. 4, 1925, pages 1591 - 1596, XP009097132 *
YOSHIDA, N. ET AL.: "Synthesis of antiinflammatory compounds. I. Synthesis and antiinflammatory activity of phenyl-substituted pyrrole derivatives", YAKUGAKU ZASSHI, vol. 93, no. 5, 1973, pages 584 - 598, XP009097090 *

Also Published As

Publication number Publication date
WO2008035359A2 (en) 2008-03-27

Similar Documents

Publication Publication Date Title
WO2008035359A3 (en) Oximinophenoxyalkanoic acid and phenylalkanoic acid derivatives
WO2007099553A3 (en) 1,3-dioxane carboxylic acids
WO2009125434A3 (en) Oxime derivatives, process for their preparation, pharmaceutical composition containing the same and medicinal use thereof
WO2009016498A8 (en) Pyrimidine and pyridine derivatives and their pharmaceutical use and compositions
WO2007135527A3 (en) Benzimidazolyl compounds
MY148634A (en) Pyridazinone derivatives
WO2007087548A3 (en) Chemical compounds
WO2007144327A3 (en) Phenyl-pyrazole derivatives as non-steroidal glucocoricoid receptor ligands
WO2007107470A3 (en) Pyrazoles as 11-beta-hsd-1
WO2009111700A3 (en) Oxadiazoanthracene compounds for the treatment of diabetes
WO2008135791A8 (en) Imidazoquinolines with immuno-modulating properties
WO2007089768A3 (en) 4-aryl-2-amino-pyrimidines or 4-aryl-2-aminoalkyl-pyrimidines as jak-2 modulators and pharmaceutical compositions containing them
WO2006082523A3 (en) Pharmaceutical sustained release composition of metformin
WO2008002244A8 (en) Imidazol-pyrimidine derivatives for treatment of diseases related to glycogen synthase kinase (gsk3)
WO2008001195A3 (en) Novel processes for the preparation of dpp iv inhibitors
WO2008000483A3 (en) Phenol derivatives for the treatment of respiratory diseases
WO2007032028A8 (en) Thiazolinones and oxazolinones and their use as ptp1b inhibitors
WO2008006795A3 (en) Indole compounds
WO2007017728A3 (en) Novel heterocyclic compounds
WO2009105969A8 (en) Epothilone analogues, their pharmaceutical compositions, their use and their preparations
MX2009006010A (en) Amine derivatives and their use in beta-2-adrenoreceptor mediated diseases.
UA96759C2 (en) 2-ARYLINDOLE DERIVATIVES AS mPGES-I INHIBITORS
WO2008074833A3 (en) Compounds
WO2008129501A3 (en) Pharmaceutical compositions of duloxetine
WO2008004100A3 (en) Therapeutic compounds

Legal Events

Date Code Title Description
DPE2 Request for preliminary examination filed before expiration of 19th month from priority date (pct application filed from 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07849663

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

NENP Non-entry into the national phase

Ref country code: RU

122 Ep: pct application non-entry in european phase

Ref document number: 07849663

Country of ref document: EP

Kind code of ref document: A2

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载